{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:56:09Z","timestamp":1793058969658,"version":"4.5.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:p>Cervical cancer screening has saved the lives of millions in regions where routine gynecologic care is readily accessible. As screening continues to evolve away from cervical cytology to primary human papillomavirus (HPV) testing, robust prospective cohort data have allowed for precise risk stratification and improved our ability to identify those at greatest risk of high-grade dysplasia and decrease unnecessary diagnostic procedures. New technologies such as p16\/Ki-67 dual stain testing and HPV methylation panels, which offer comparable performance to co-testing and can be developed into high-throughput workflows, could lead to a fully molecular Pap test. Self-sampling in the United States, where the initial screen can be done in the home, in conjunction with new screening technologies, may decrease the existing hurdles of routine cervical cancer screening. Implementation barriers include issues with workflow, workforce, and cost. These need to be addressed to achieve an improved and more equitable cervical cancer screening program in the United States.<\/jats:p>","DOI":"10.1097\/aog.0000000000005393","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T19:15:33Z","timestamp":1694718933000},"page":"1036-1043","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Primary Human Papillomavirus Testing and Other New Technologies for Cervical Cancer Screening"],"prefix":"10.1097","volume":"142","author":[{"given":"Mark H.","family":"Einstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Gabor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikrant V.","family":"Sahasrabuddhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,9,13]]},"reference":[{"key":"R1-20260916","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0959-8049(05)80359-4","article-title":"Cervical cancer incidence and mortality trends in Finland and Estonia: a screened vs. an unscreened population","volume":"29","author":"Aareleid","year":"1993","journal-title":"Eur J Cancer"},{"key":"R2-20260916","doi-asserted-by":"crossref","first-page":"e900","DOI":"10.1136\/bmj.e900","article-title":"Screening and cervical cancer cure: population based cohort study","volume":"344","author":"Andrae","year":"2012","journal-title":"Br Med J"},{"issue":"suppl 1","key":"R4-20260916","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/LGT.0b013e318287d329","article-title":"2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors","volume":"17","author":"Massad","year":"2013","journal-title":"J Lower Genital Tract Dis"},{"key":"R5-20260916","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/ijc.27750","article-title":"Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia","volume":"132","author":"Mirabello","year":"2013","journal-title":"Int J Cancer"},{"key":"R6-20260916","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/LGT.0000000000000525","article-title":"2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors","volume":"24","author":"Perkins","year":"2020","journal-title":"J Lower Genital Tract Dis"},{"key":"R7-20260916","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/LGT.0000000000000343","article-title":"Risks of CIN 2+, CIN 3+, and cancer by cytology and human papillomavirus status: the foundation of risk-based cervical screening guidelines","volume":"21","author":"Demarco","year":"2017","journal-title":"J Lower Genital Tract Dis"},{"key":"R8-20260916","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1097\/AOG.0000000000001721","article-title":"Similar risk patterns after cervical screening in two large US populations: implications for clinical guidelines","volume":"128","author":"Gage","year":"2016","journal-title":"Obstet Gynecol"},{"key":"R9-20260916","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/1055-9965.EPI-15-0669","article-title":"Risk stratification using human papillomavirus testing among women with equivocally abnormal cytology: results from a state-wide surveillance program","volume":"25","author":"Gage","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R10-20260916","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/jnci\/djx225","article-title":"Relative performance of HPV and cytology components of cotesting in cervical screening","volume":"110","author":"Schiffman","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"R11-20260916","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/cncr.22353","article-title":"Impact of the national Breast and cervical cancer early detection program on mammography and Pap test utilization among White, Hispanic, and African American women: 1996\u20132000","volume":"109","author":"Adams","year":"2007","journal-title":"Cancer"},{"key":"R14-20260916","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"key":"R15-20260916","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/01.ogx.0000549540.69362.81","article-title":"Screening for cervical cancer: US preventive services task force recommendation statement","volume":"73","author":"Curry","year":"2018","journal-title":"Obstet Gynecol Surv"},{"key":"R16-20260916","doi-asserted-by":"crossref","first-page":"698","DOI":"10.15585\/mmwr.mm6832a3","article-title":"Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices","volume":"68","author":"Meites","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R17-20260916","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ygyno.2014.12.022","article-title":"Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance","volume":"136","author":"Huh","year":"2015","journal-title":"Gynecol Oncol"},{"key":"R18-20260916","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1158\/1055-9965.EPI-20-1003","article-title":"Cervical cancer screening: comparison of conventional Pap smear test, liquid-based cytology, and human papillomavirus testing as stand-alone or cotesting strategies","volume":"30","author":"Liang","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R19-20260916","doi-asserted-by":"crossref","first-page":"dju153","DOI":"10.1093\/jnci\/dju153","article-title":"Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test","volume":"106","author":"Gage","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"R20-20260916","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta23280","article-title":"HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT","volume":"23","author":"Gilham","year":"2019","journal-title":"Health Technol Assess"},{"key":"R21-20260916","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/OGX.0000000000000608","article-title":"Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial","volume":"73","author":"Ogilvie","year":"2018","journal-title":"Obstet Gynecol Surv"},{"key":"R22-20260916","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/ijc.30579","article-title":"Eurogin 2016 roadmap: how HPV knowledge is changing screening practice","volume":"140","author":"Wentzensen","year":"2017","journal-title":"Int J Cancer"},{"key":"R23-20260916","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/ijc.34039","article-title":"Human papillomavirus\u2010based screening at extended intervals missed fewer cervical precancers than cytology in the HPV for Cervical Cancer (HPV FOCAL) trial","volume":"151","author":"Gottschlich","year":"2022","journal-title":"Int J Cancer"},{"key":"R26-20260916","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1093\/jnci\/djt235","article-title":"Screening for cervical cancer precursors with p16\/Ki-67 dual-stained cytology: results of the PALMS study","volume":"105","author":"Ikenberg","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"R27-20260916","doi-asserted-by":"crossref","first-page":"djv257","DOI":"10.1093\/jnci\/djv257","article-title":"p16\/Ki-67 dual stain cytology for detection of cervical precancer in HPV-positive women","volume":"107","author":"Wentzensen","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"R28-20260916","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/cncy.21800","article-title":"Interobserver reproducibility of cytologic p16INK4a\/Ki\u201067 dual immunostaining in human papillomavirus\u2010positive women","volume":"125","author":"Benevolo","year":"2017","journal-title":"Cancer Cytopathol"},{"key":"R29-20260916","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/jamaoncol.2018.4270","article-title":"Five-year risk of cervical precancer following p16\/Ki-67 dual-stain triage of HPV-positive women","volume":"5","author":"Clarke","year":"2019","journal-title":"JAMA Oncol"},{"key":"R30-20260916","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jamainternmed.2019.0306","article-title":"Clinical evaluation of human papillomavirus screening with p16\/Ki-67 dual stain triage in a large organized cervical cancer screening program","volume":"179","author":"Wentzensen","year":"2019","journal-title":"JAMA Intern Med"},{"key":"R31-20260916","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/jnci\/djaa066","article-title":"Accuracy and efficiency of deep-learning\u2013based automation of dual stain cytology in cervical cancer screening","volume":"113","author":"Wentzensen","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"R32-20260916","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ygyno.2016.10.031","article-title":"Triaging HPV-positive women with p16\/Ki-67 dual-stained cytology: results from a sub-study nested into the ATHENA trial","volume":"144","author":"Wright","year":"2017","journal-title":"Gynecol Oncol"},{"key":"R33-20260916","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/ijc.33812","article-title":"Clinical validation of p16\/Ki\u201067 dual\u2010stained cytology triage of HPV\u2010positive women: results from the IMPACT trial","volume":"150","author":"Wright","year":"2022","journal-title":"Int J Cancer"},{"key":"R34-20260916","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1101\/gad.2037511","article-title":"CpG islands and the regulation of transcription","volume":"25","author":"Deaton","year":"2011","journal-title":"Genes Develop"},{"key":"R35-20260916","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1056\/NEJMra023075","article-title":"Gene silencing in cancer in association with promoter hypermethylation","volume":"349","author":"Herman","year":"2003","journal-title":"N Engl J Med"},{"key":"R36-20260916","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1158\/1078-0432.CCR-17-3251","article-title":"Human papillomavirus DNA methylation as a biomarker for cervical precancer: consistency across 12 genotypes and potential impact on management of HPV-positive women","volume":"24","author":"Clarke","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R37-20260916","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ygyno.2011.01.013","article-title":"Methylation of HPV16 genome CpG sites is associated with cervix precancer and cancer","volume":"121","author":"Sun","year":"2011","journal-title":"Gynecol Oncol"},{"key":"R38-20260916","doi-asserted-by":"crossref","first-page":"62133","DOI":"10.18632\/oncotarget.11390","article-title":"A polycomb-mediated epigenetic field defect precedes invasive cervical carcinoma","volume":"7","author":"Wijetunga","year":"2016","journal-title":"Oncotarget"},{"key":"R39-20260916","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ebiom.2019.10.053","article-title":"The use of human papillomavirus DNA methylation in cervical intraepithelial neoplasia: a systematic review and meta-analysis","volume":"50","author":"Bowden","year":"2019","journal-title":"EBioMedicine"},{"key":"R40-20260916","doi-asserted-by":"crossref","first-page":"k4823","DOI":"10.1136\/bmj.k4823","article-title":"Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses","volume":"363","author":"Arbyn","year":"2018","journal-title":"BMJ"},{"key":"R41-20260916","doi-asserted-by":"crossref","first-page":"109","DOI":"10.15585\/mmwr.mm7004a1","article-title":"Impact of COVID-19 on cervical cancer screening rates among women aged 21\u201365 years in a large integrated health care system\u2014Southern California, January 1\u2013September 30, 2019, and January 1\u2013September 30, 2020","volume":"70","author":"Miller","year":"2021","journal-title":"MMWR Morbid Mortal Weekly Rep"},{"key":"R42-20260916","doi-asserted-by":"crossref","first-page":"e234052","DOI":"10.1001\/jamanetworkopen.2023.4052","article-title":"Economic evaluation of mailed home-based human papillomavirus self-sampling kits for cervical cancer screening","volume":"6","author":"Meenan","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R43-20260916","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1002\/cam4.3951","article-title":"A population study of screening history and diagnostic outcomes of women with invasive cervical cancer","volume":"10","author":"Benard","year":"2021","journal-title":"Cancer Med"},{"key":"R44-20260916","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ygyno.2020.08.033","article-title":"A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States","volume":"159","author":"Landy","year":"2020","journal-title":"Gynecol Oncol"},{"key":"R45-20260916","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/jnci\/dji115","article-title":"Cervical cancer in women with comprehensive health care access: attributable factors in the screening process","volume":"97","author":"Leyden","year":"2005","journal-title":"J Natl Cancer Inst"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005393","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:04:32Z","timestamp":1789556672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,13]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000005393","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,13]]},"assertion":[{"value":"2023-04-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}